BNP Paribas Financial Markets’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.5M | Sell |
664,890
-69,259
| -9% | -$949K | ﹤0.01% | 1556 |
|
|
2026
Q1 | $9.13M | Buy |
734,149
+30,485
| +4% | +$409K | ﹤0.01% | 1621 |
|
|
2025
Q4 | $8.87M | Buy |
703,664
+364,801
| +108% | +$4.17M | ﹤0.01% | 1690 |
|
|
2025
Q3 | $3.39M | Buy |
338,863
+133,997
| +65% | +$1.2M | ﹤0.01% | 2250 |
|
|
2025
Q2 | $1.66M | Buy |
204,866
+100,280
| +96% | +$756K | ﹤0.01% | 2601 |
|
|
2025
Q1 | $876K | Sell |
104,586
-63,608
| -38% | -$531K | ﹤0.01% | 2881 |
|
|
2024
Q4 | $1.33M | Buy |
168,194
+113,796
| +209% | +$955K | ﹤0.01% | 2636 |
|
|
2024
Q3 | $453K | Sell |
54,398
-402,852
| -88% | -$3.15M | ﹤0.01% | 2905 |
|
|
2024
Q2 | $2.9M | Buy |
457,250
+358,058
| +361% | +$2.27M | ﹤0.01% | 1702 |
|
|
2024
Q1 | $601K | Buy |
99,192
+38,031
| +62% | +$214K | ﹤0.01% | 2747 |
|
|
2023
Q4 | $371K | Sell |
61,161
-20,106
| -25% | -$89.6K | ﹤0.01% | 2959 |
|
|
2023
Q3 | $343K | Buy |
81,267
+15,548
| +24% | +$58K | ﹤0.01% | 2900 |
|
|
2023
Q2 | $204K | Sell |
65,719
-56,875
| -46% | -$121K | ﹤0.01% | 3011 |
|
|
2023
Q1 | $170K | Buy |
122,594
+42,053
| +52% | +$83.7K | ﹤0.01% | 3198 |
|
|
2022
Q4 | $160K | Sell |
80,541
-6,598
| -8% | -$14.8K | ﹤0.01% | 3082 |
|
|
2022
Q3 | $176K | Sell |
87,139
-22,379
| -20% | -$62.7K | ﹤0.01% | 3552 |
|
|
2022
Q2 | $348K | Sell |
109,518
-26,492
| -19% | -$96K | ﹤0.01% | 2848 |
|
|
2022
Q1 | $567K | Sell |
136,010
-31,615
| -19% | -$140K | ﹤0.01% | 2684 |
|
|
2021
Q4 | $803K | Buy |
167,625
+105,925
| +172% | +$528K | ﹤0.01% | 2737 |
|
|
2021
Q3 | $329K | Buy |
61,700
+24,756
| +67% | +$125K | ﹤0.01% | 2899 |
|
|
2021
Q2 | $189K | Sell |
36,944
-9,035
| -20% | -$51.4K | ﹤0.01% | 2879 |
|
|
2021
Q1 | $309K | Sell |
45,979
-5,660
| -11% | -$31.4K | ﹤0.01% | 2835 |
|
|
2020
Q4 | $236K | Sell |
51,639
-2,185
| -4% | -$9.68K | ﹤0.01% | 2804 |
|
|
2020
Q3 | $209K | Sell |
53,824
-167,218
| -76% | -$715K | ﹤0.01% | 2742 |
|
|
2020
Q2 | $1.05M | Buy |
221,042
+152,103
| +221% | +$626K | ﹤0.01% | 1789 |
|
|
2020
Q1 | $240K | Buy |
68,939
+20,386
| +42% | +$86.3K | ﹤0.01% | 2764 |
|
|
2019
Q4 | $234K | Sell |
48,553
-1,687
| -3% | -$5.86K | ﹤0.01% | 2883 |
|
|
2019
Q3 | $146K | Buy |
50,240
+37,686
| +300% | +$131K | ﹤0.01% | 2918 |
|
|
2019
Q2 | $90K | Sell |
12,554
-7,873
| -39% | -$80.5K | ﹤0.01% | 3095 |
|
|
2019
Q1 | $289K | Buy |
20,427
+18,062
| +764% | +$239K | ﹤0.01% | 2465 |
|
|
2018
Q4 | $32K | Sell |
2,365
-2,978
| -56% | -$53.7K | ﹤0.01% | 2931 |
|
|
2018
Q3 | $119K | Buy |
5,343
+586
| +12% | +$12.3K | ﹤0.01% | 2656 |
|
|
2018
Q2 | $78.1K | Buy |
+4,757
| New | +$83.5K | ﹤0.01% | 2916 |
|
Other funds holding AMRX
BNP Paribas Financial Markets's AMRX Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Amneal Pharmaceuticals (AMRX) stake by 9.4% in Q2 2026, selling an estimated $949K and leaving 664,890 shares worth $11.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.
BNP Paribas Financial Markets first reported a position in AMRX in Q2 2018 and has held it in 33 quarters since. 288 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- BNP Paribas Financial Markets held 664,890 shares of Amneal Pharmaceuticals worth $11.5M as of Q2 2026.
- BNP Paribas Financial Markets sold 69,259 Amneal Pharmaceuticals shares in Q2 2026, an estimated $949K.
- Amneal Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #1556 holding.
- BNP Paribas Financial Markets first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 288 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.